Arsthinol nanosuspensions: Pharmacokinetics and anti-leukaemic activity on NB4 promyelocytic leukaemia cells

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 10, 2009, Pages 1295-1301

  Ajana, Imane ^a   Astier, Alain ^a   Gibaud, Stéphane ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Anti leukaemic activity; Arsthinol; Nanosuspensions; Pharmacokinetics

Indexed keywords

ARSTHINOL; HERBACEOUS AGENT; MELARSOPROL; NANOPARTICLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ORGANOARSENIC DERIVATIVE; OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; BRAIN DISEASE; CANCER GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG INHIBITION; DRUG SOLUBILITY; DRUG STRUCTURE; FEMALE; HYPERBARISM; IC 50; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PROMYELOCYTIC LEUKEMIA; RISK FACTOR; TISSUE DISTRIBUTION; ANIMAL; BRAIN; CELL PROLIFERATION; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; DRUG SCREENING; HUMAN; METABOLISM; METHODOLOGY; MOUSE STRAIN; NANOTECHNOLOGY; SUSPENSION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; BONE MARROW; BRAIN; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MELARSOPROL; MICE; MICE, INBRED STRAINS; NANOTECHNOLOGY; OXIDES; SUSPENSIONS;

EID: 85047686325     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.10.0004     Document Type: Article

References (41)

1. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-3360.
2. Friedheim EAH, Berman RL. Effect of BAL on trichomonacidal activity of some organic arsenicals. Proc Soc Exp Biol Med 1947; 65: 180-182.
3. Friedheim EAH. Heterocyclic metal and sulfur organic compounds. 1953; US Patent 2,664,432.
4. Burri C et al. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 2000; 355: 1419-1425.
5. Burri C et al. Pharmacokinetic properties of the trypanocidal drug melarsoprol. Chemotherapy 1993; 39: 225-234.
6. Brown CH et al. Intestinal amebiasis: incidence, symptoms, and treatment with arsthinol (Balarsen). JAMA 1956; 160: 360-363.
7. Goldman L et al. Arsthinol (Balarsen) in dermatology. Dermatologica 1956; 113: 369-374.
8. Gibaud S, Astier A. [Organoarsenicals derived from 2-phenyl-[1,3,2] dithiarsolan-4-yl)-methanol (AsIII) with antileukaemic properties: from trypanosomicides to anticancer drugs]. Ann Pharm Fr 2007; 65: 162-168 [in French].
9. Astier A, Gibaud S. Use of organoarsenic or organoantimony derivatives for their anticancer properties. 2005; Patent WO/ 2005/034935 A1.
10. Hiskey CF, Cantwell FF. Ultraviolet spectrum correlations with the conjugate acid-base species of acetarsone and arsthinol. J Pharm Sci 1968; 57: 2105-2111.
11. Anon. New and nonofficial remedies; arsthinol. JAMA 1953; 152: 531.
12. Ben Zirar S et al. Comparison of nanosuspensions and hydroxypropyl-ß-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice. Eur J Pharm Biopharm 2008; 70: 649-656.
13. Gibaud S et al. Increased bone marrow toxicity of doxorubicin bound to nanoparticles. Eur J Cancer 1994; 6: 820-826.
14. Gibaud S et al. Cells involved in the capture of nanoparticles in hematopoietic organs. J Pharm Sci 1996; 85: 944-950.
15. Gibaud S et al. [Targeting bone marrow with the help of polyalkylcyanoacrylate nanoparticles]. Ann Pharm Fr 1999; 57: 324-331 [in French].
16. Konig A et al. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 1997; 90: 562-570.
17. Jing Y et al. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94: 2102-2111.
18. Gibaud S et al. (2-Phenyl-[1, 3, 2] dithiarsolan-4-yl)-methanol derivatives show in vitro antileukemic activity. J Organomet Chem 2006; 691: 1081-1084.
19. Müller RH et al. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution. 1999; US Patent 5,858,410.
20. Elliot SC, Loper BR. Improved absorption tube for arsenic determinations. Anal Chem 1974; 46: 2256-2257.
21. Hansen MB et al. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989; 119: 203-210.
22. Davis MA, Taube RA. Pulmonary perfusion imaging: acute toxicity and safety factors as a function of particle size. J Nucl Med 1978; 19: 1209-1213.
23. Schroeder HG et al. Physiological effects of subvisible microspheres administered intravenously to beagle dogs. J Pharm Sci 1978; 67: 508-513.
24. Slack JD et al. Acute hemodynamic effects and blood pool kinetics of polystyrene microspheres following intravenous administration. J Pharm Sci 1981; 70: 660-664.
25. Müller RH, Jacobs C. Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int J Pharm 2002; 237: 151-161.
26. Friedheim EAH. A five day peroral treatment of yaws with STB, a new trivalent arsenical. Am J Trop Med Hyg 1949; s1-s29: 185.
27. Levy JS, Talley RW. Effectiveness of balarsen (mercaptoarsenal) in treatment of amebiasis. Gastroenterology 1952; 22: 588-597.
28. Gherardi RK et al. Organic arsenic-induced Guillain-Barrelike syndrome due to melarsoprol: a clinical, electrophysiological, and pathological study. Muscle Nerve 1990; 13: 637-645.
29. Vahidnia A et al. Arsenic neurotoxicity - a review. Hum Exp Toxicol 2007; 26: 823-832.
30. Burri C et al. Pharmacokinetics of melarsoprol in uninfected vervet monkeys. Acta Trop 1994; 58: 35-49.
31. Berger BJ, Fairlamb AH. Properties of melarsamine hydrochloride (Cymelarsan) in aqueous solution. Antimicrob Agents Chemother 1994; 38: 1298-1302.
32. Fairlamb AH et al. Trypanothione is the primary target for arsenical drugs against African trypanosomes. Proc Natl Acad Sci USA 1989; 86: 2607-2611.
33. Minden H, Rothe R. The biochemical mode of operation of arsenic. Internationales Archiv für Gewerbepathologie und Gewerbehygiene 1968; 24: 359-366.
34. Schmidt A-C et al. Mass spectrometric evidence for different complexes of peptides and proteins with arsenic (III), arsenic (V), copper (II), and zinc (II) species. Rapid Commun Mass Spectrom 2007; 21: 153-163.
35. Wang ZG et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood 1998; 92: 1497-1504.
36. Dai J et al. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93: 268-277.
37. Koshiuka K et al. Novel therapeutic approach: organic arsenical melarsoprol alone or with all-trans-retinoic acid markedly inhibit growth of human breast and prostate cancer cells in vitro and in vivo. Br J Cancer 2000; 82: 452-458.
38. Rabinow B et al. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int J Pharm 2007; 339: 251-260.
39. Peters K et al. Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother 2000; 45: 77-83.
40. Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx 2005; 2: 108-119.
41. Liu JW et al. Metallothionein-I/II null mice are more sensitive than wild-type mice to the hepatotoxic and nephrotoxic effects of chronic oral or injected inorganic arsenicals. Toxicol Sci 2000; 55: 460-467.